Tasigna® is the commercial brand name of Nilotinib Capsules, a second-generation tyrosine kinase inhibitor (TKI) developed by Novartis. It exerts its anti-tumor activity by selectively inhibiting the BCR-ABL tyrosine kinase, thereby suppressing the proliferation of BCR-ABL-positive leukemic cells. Main IndicationsTreatment…
Ruibikang® is the commercial brand name of Oteseconazole Capsules, a novel, orally active azole antifungal agent developed by Hengrui Medicine. It exerts antifungal effects by inhibiting fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis and disrupting the fungal cell…
CRESEMBA® is the commercial brand name of Isavuconazonium Sulfate Capsules, a novel triazole antifungal agent developed by Basilea Pharmaceutica Deutschland GmbH. As a prodrug, it is rapidly converted in vivo to isavuconazole, which exerts its antifungal activity by inhibiting the…
NEFECON® is the commercial brand name of Budesonide Enteric Capsules, a targeted, delayed-release formulation of the synthetic corticosteroid budesonide developed by Everest Medicines. It is designed to deliver budesonide locally to the ileum, modulating the mucosal immune response to reduce…
MaiFantuo® is the commercial brand name of Mavacamten, a first-in-class, allosteric and reversible cardiac myosin inhibitor developed by Bristol Myers Squibb. It works by reducing excessive actin-myosin cross-bridge formation, thereby decreasing hypercontractility of the heart muscle and improving left ventricular…
Evrenzo® is the commercial brand name of Roxadustat, an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It stabilizes hypoxia-inducible factor (HIF), thereby stimulating endogenous erythropoietin production and improving iron utilization to treat anemia. Main Indications Treatment of anemia associated…
Linzess® is the commercial brand name of Linaclotide, an orally administered guanylate cyclase-C (GC-C) agonist developed by Ironwood Pharmaceuticals and marketed by AstraZeneca in China. It acts locally on the intestinal epithelium to increase intestinal fluid secretion and accelerate transit,…
Cerezyme® (generic name: imiglucerase) is an enzyme replacement therapy (ERT) developed by Sanofi Genzyme for Gaucher disease. It is a recombinant DNA-derived analog of human β-glucocerebrosidase, which catalyzes the hydrolysis of accumulated glucocerebroside into glucose and ceramide to reduce toxic…
Dorner® is the commercial brand name of Beraprost sodium, an orally active prostacyclin (PGI2) analogue developed by Toray Industries of Japan. It acts on prostacyclin receptors on blood vessels and platelets to dilate blood vessels and inhibit platelet aggregation, thus…